IGC Pharma (AMEX:IGC) reported quarterly losses of $(0.02) per share which met the analyst consensus estimate. This is unchanged from the same period last year. The company reported quarterly sales of $191.000 thousand which missed the analyst consensus estimate of $325.000 thousand by 41.23 percent. This is a 53.64 percent decrease over sales of $412.000 thousand the same period last year.